Approved This Year
Approved This Year: tracked and updated as new reporting lands.
Novo Nordisk CEO Warns of Growing Competition in Obesity Drug Market
Novo Nordisk's CEO believes investors are underestimating the demand for differentiation among obesity drugs, and that new treatment options like...
FDA Clears Bristol Myers Squibb's Oral Multiple Myeloma Therapy, Introducing First-in-Class Agent
The U.S. FDA has approved Bristol Myers Squibb’s oral drug iberdomide, marketed as Zenbexus, for use with daratumumab and dexamethasone in patients...
FDA Approves Bristol Myers Squibb’s Zenbexus for Advanced Multiple Myeloma, Marking Debut of New Drug Class
The U.S. FDA has approved Zenbexus, Bristol Myers Squibb’s oral treatment for advanced multiple myeloma, introducing a new class of blood cancer...